Related Experiment Video

Updated: Mar 2, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

E3 ligase LMO7 enhances temozolomide sensitivity by promoting MGMT degradation in lung cancer

Jiabing Li1, Xiaorong Feng1, Yunfang Deng1

  • 1The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, Hunan, China.

The Journal of Biological Chemistry
|February 28, 2026
PubMed

Insights

The E3 ubiquitin ligase LIM domain only 7 (LMO7) promotes the degradation of O6-methylguanine-DNA methyltransferase (MGMT), enhancing temozolomide (TMZ) sensitivity in non-small cell lung cancer (NSCLC). Lower LMO7 and higher MGMT levels correlate with poorer survival in lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Temozolomide (TMZ) is a key chemotherapy for brain tumors and non-small cell lung cancer (NSCLC) brain metastases.
  • Therapeutic resistance to TMZ is often mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).

Purpose of the Study:

  • To identify novel regulators of TMZ sensitivity in NSCLC.
  • To investigate the role of LIM domain only 7 (LMO7) in modulating MGMT levels and TMZ efficacy.

Main Methods:

  • Investigated the interaction between LMO7 and MGMT using biochemical assays.
  • Assessed the effect of LMO7 on MGMT ubiquitination and proteasomal degradation.
  • Analyzed patient datasets to correlate LMO7 and MGMT expression with clinical outcomes.

Main Results:

  • Identified LMO7 as an E3 ubiquitin ligase that directly binds and promotes the proteasomal degradation of MGMT.
  • Demonstrated that LMO7-mediated MGMT degradation enhances TMZ sensitivity in NSCLC cells.
  • Discovered a positive feedback loop where TMZ treatment strengthens the LMO7-MGMT interaction, further accelerating MGMT degradation.
  • Found that low LMO7 expression and high MGMT expression in lung cancer patients correlate with significantly shorter overall survival.

Conclusions:

  • LMO7-mediated degradation of MGMT is a critical mechanism for increasing TMZ sensitivity in NSCLC.
  • LMO7 represents a potential prognostic biomarker for lung cancer patients.
  • Targeting LMO7 could be a novel therapeutic strategy to overcome TMZ resistance.
Keywords:
E3 ligaseLMO7MGMTNSCLCchemoresistancetemozolomideubiquitination

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.9K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K